Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
World game at war: why some European nations have threatened a World Cup boycott 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
RALEIGH, N.C., April 30, 2018 -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close and will host a conference call and webcast on Thursday, May 10, 2018, at 4:30 PM Eastern Time.
| Conference Call & Webcast | |||||
| Thursday, May 10 @ 4:30pm Eastern Time | |||||
| Domestic: | 800-289-0438 | ||||
| International: | 323-794-2423 | ||||
| Passcode: | 5157508 | ||||
| Webcast: | http://public.viavid.com/index.php?id=129149 | ||||
| Replays available through May 24: | |||||
| Domestic: | 844-512-2921 | ||||
| International: | 412-317-6671 | ||||
| Conference ID: | 5157508 | ||||
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.
For more information, please visit or follow us:
| Internet: | www.bdsi.com | ||||
| Facebook: | Facebook.com/BioDeliverySI | ||||
| Twitter: | @BioDeliverySI |
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. ("BDSI") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI's management and are subject to significant risks and uncertainties, including those detailed in the BDSI's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s commercialization programs for BELBUCA and BUNAVAIL based on the products attributes described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI's control). BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.
© 2018 BioDelivery Sciences International, Inc. All rights reserved.
Contact
Al Medwar
BioDelivery Sciences
919-582-9050
[email protected]
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
[email protected]
